These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30182192)

  • 21. Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure.
    Doumas M; Faselis C; Kokkinos P; Anyfanti P; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2014 Jan; 12(1):30-7. PubMed ID: 23905599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.
    de Leeuw PW; Bisognano JD; Bakris GL; Nadim MK; Haller H; Kroon AA;
    Hypertension; 2017 May; 69(5):836-843. PubMed ID: 28320856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension.
    Alnima T; Scheffers I; De Leeuw PW; Winkens B; Jongen-Vancraybex H; Tordoir JH; Schmidli J; Mohaupt MG; Allemann Y; Kroon AA
    J Hypertens; 2012 Aug; 30(8):1665-70. PubMed ID: 22728906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baroreflex activation therapy lowers arterial pressure without apparent stimulation of the carotid bodies.
    Alnima T; Goedhart EJ; Seelen R; van der Grinten CP; de Leeuw PW; Kroon AA
    Hypertension; 2015 Jun; 65(6):1217-22. PubMed ID: 25941348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
    Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carotid baroreflex activation therapy for resistant hypertension.
    Victor RG
    Nat Rev Cardiol; 2015 Aug; 12(8):451-63. PubMed ID: 26149485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baroreceptor Stimulation for Resistant Hypertension.
    Yoruk A; Bisognano JD; Gassler JP
    Am J Hypertens; 2016 Dec; 29(12):1319-1324. PubMed ID: 27444637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endovascular Baroreflex Amplification for Resistant Hypertension.
    van Kleef MEAM; Bates MC; Spiering W
    Curr Hypertens Rep; 2018 May; 20(5):46. PubMed ID: 29744599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights.
    Grassi G; Brambilla G; Pizzalla DP; Seravalle G
    Curr Hypertens Rep; 2016 Aug; 18(8):60. PubMed ID: 27334011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baroreflex Amplification and Carotid Body Modulation for the Treatment of Resistant Hypertension.
    Groenland EH; Spiering W
    Curr Hypertens Rep; 2020 Mar; 22(4):27. PubMed ID: 32166464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.
    Wallbach M; Born E; Kämpfer D; Lüders S; Müller GA; Wachter R; Koziolek MJ
    Clin Res Cardiol; 2020 Apr; 109(4):513-522. PubMed ID: 31388741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review.
    Schmidt R; Rodrigues CG; Schmidt KH; Irigoyen MCC
    ESC Heart Fail; 2020 Feb; 7(1):3-14. PubMed ID: 31965746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistant hypertension: baroreflex stimulation as a new tool.
    Menne J; Jordan J; Linnenweber-Held S; Haller H
    Nephrol Dial Transplant; 2013 Feb; 28(2):288-95. PubMed ID: 23223217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective.
    Halbach M; Fritz T; Madershahian N; Pfister R; Reuter H
    Curr Heart Fail Rep; 2016 Apr; 13(2):71-6. PubMed ID: 26879389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients.
    Mann JA; Abraham WT
    Curr Heart Fail Rep; 2019 Feb; 16(1):38-46. PubMed ID: 30762177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis.
    Chunbin W; Fu S; Jing H
    Clin Exp Hypertens; 2018; 40(6):501-508. PubMed ID: 29624472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction.
    Gronda E; Seravalle G; Trevano FQ; Costantino G; Casini A; Alsheraei A; Lovett EG; Vanoli E; Mancia G; Grassi G
    J Hypertens; 2015 Aug; 33(8):1704-8. PubMed ID: 26132760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of interventional management of hypertension: threats and opportunities.
    Briasoulis A; Bakris G
    Curr Vasc Pharmacol; 2014 Jan; 12(1):69-76. PubMed ID: 23905592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?
    Bolignano D; Coppolino G
    Rev Cardiovasc Med; 2018 Sep; 19(3):89-95. PubMed ID: 31054557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baropacing as a new option for treatment of resistant hypertension.
    Alnima T; de Leeuw PW; Kroon AA
    Eur J Pharmacol; 2015 Sep; 763(Pt A):23-7. PubMed ID: 25987419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.